CSL Limited
(ASX:CSL) has become aware that biotech health company, Bioverativ, has filed patent infringement complaints in the US District Court for the District of Delaware and with the International Trade Commission.
Bioverativ alleges that the use of Idelvion®, which is used to assist patients with hemophilia B, infringes on three of its patents.
CSL says Idelvion® has been developed by CSL Behring, with over a decade of innovative research, and it will vigorously defend against the claim. The company says it is highly confident of its intellectual property position.
CSL says it believes patients and physicians have the right to choose among a variety of treatment options for hemophilia B, including Idelvion® .
Shares in CSL Limited
(ASX:CSL) are trading 0.6 per cent higher to $134.96.
